Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.

about

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.

Item

http://www.wikidata.org/entity/Q36391682

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Simeprevir with peginterferon ...... an open-label, rollover study.

@ast

Simeprevir with peginterferon ...... an open-label, rollover study.

@en

type

Item

label

Simeprevir with peginterferon ...... an open-label, rollover study.

@ast

Simeprevir with peginterferon ...... an open-label, rollover study.

@en

prefLabel

Simeprevir with peginterferon ...... an open-label, rollover study.

@ast

Simeprevir with peginterferon ...... an open-label, rollover study.

@en

P1476

Simeprevir with peginterferon ...... an open-label, rollover study.

@en

P2093

Bart Fevery

http://www.w3.org/2001/XMLSchema#string

Chris Corbett

http://www.w3.org/2001/XMLSchema#string

Edward J Gane

http://www.w3.org/2001/XMLSchema#string

Edwin DeJesus

http://www.w3.org/2001/XMLSchema#string

Henk Reesink

http://www.w3.org/2001/XMLSchema#string

Holger Hinrichsen

http://www.w3.org/2001/XMLSchema#string

Jacob George

http://www.w3.org/2001/XMLSchema#string

Maria Beumont

http://www.w3.org/2001/XMLSchema#string

Mariliza Hendrique Da Silva

http://www.w3.org/2001/XMLSchema#string

Moises Diago

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study.

Telaprevir for previously treated chronic HCV infection.

Side effects of therapy of hepatitis C and their management.

Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.

Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.

P2888

s12879-017-2444-3

P304

389

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12879-017-2444-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Igor Nikitin

Ewa Janczewska

P577

2017-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085750466

http://www.w3.org/2001/XMLSchema#string

P698

28577353

http://www.w3.org/2001/XMLSchema#string

P932

5457573

http://www.w3.org/2001/XMLSchema#string